José P S Henriques

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6687688/publications.pdf

Version: 2024-02-01

252 papers

13,760 citations

20817 60 h-index 24258 110 g-index

264 all docs 264 docs citations

times ranked

264

9907 citing authors

#	Article	IF	CITATIONS
1	DEtection of ProxImal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). European Radiology, 2022, 32, 143-151.	4.5	10
2	Response shift after coronary revascularization. Quality of Life Research, 2022, 31, 437-450.	3.1	8
3	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. International Journal of Cardiovascular lmaging, 2022, 38, 631-641.	1.5	1
4	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	13.7	34
5	Deep learning-based whole-heart segmentation in 4D contrast-enhanced cardiac CT. Computers in Biology and Medicine, 2022, 142, 105191.	7.0	8
6	Identification and treatment of the vulnerable coronary plaque. Reviews in Cardiovascular Medicine, 2022, 23, 1.	1.4	10
7	Collagenase to facilitate guidewire crossing in chronic total occlusion PCl—The Total Occlusion Study in Coronary Arteriesâ€5 (TOSCAâ€5) trial. Catheterization and Cardiovascular Interventions, 2022, 99, 1065-1073.	1.7	6
8	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. Journal of Clinical Medicine, 2022, 11, 1361.	2.4	14
9	External validation of the GRACE risk score and the risk–treatment paradox in patients with acute coronary syndrome. Open Heart, 2022, 9, e001984.	2.3	10
10	Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention, 2022, 17, 1340-1347.	3.2	10
11	Cost Analysis From a Randomized Comparison of Immediate Versus Delayed Angiography After Cardiac Arrest. Journal of the American Heart Association, 2022, 11, e022238.	3.7	0
12	Evaluation of a Fully Automatic Deep Learning-Based Method for the Measurement of Psoas Muscle Area. Frontiers in Nutrition, 2022, 9, .	3.7	8
13	Ischaemic electrocardiogram patterns and its association with survival in out-of-hospital cardiac arrest patients without ST-segment elevation myocardial infarction: a COACT trials' post-hoc subgroup analysis. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 535-543.	1.0	2
14	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusion—A subanalysis of the EXPLORE trial. Catheterization and Cardiovascular Interventions, 2021, 97, 1176-1183.	1.7	2
15	Time to Return of Spontaneous Circulation and Survival: When to Transport in out-of-Hospital Cardiac Arrest?. Prehospital Emergency Care, 2021, 25, 171-181.	1.8	21
16	Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: aÂsystematic review and meta-analysis of randomised trials. Netherlands Heart Journal, 2021, 29, 30-41.	0.8	10
17	Sex differences in patients with out-of-hospital cardiac arrest without ST-segment elevation: A COACT trial substudy. Resuscitation, 2021, 158, 14-22.	3.0	5
18	Impella CP Implantation during Cardiopulmonary Resuscitation for Cardiac Arrest: A Multicenter Experience. Journal of Clinical Medicine, 2021, 10, 339.	2.4	10

#	Article	IF	Citations
19	Continuous postoperative pericardial flushing reduces postoperative bleeding after coronary artery bypass grafting: A randomized trial. EClinicalMedicine, 2021, 31, 100661.	7.1	1
20	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. European Heart Journal, 2021, 42, 1038-1046.	2.2	28
21	Update and, internal and temporal-validation of the FRANCE-2 and ACC-TAVI early-mortality prediction models for Transcatheter aortic Valve Implantation (TAVI) using data from the Netherlands heart registration (NHR). IJC Heart and Vasculature, 2021, 32, 100716.	1.1	4
22	Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis. ESC Heart Failure, 2021, 8, 953-961.	3.1	10
23	Online Quantitative Aortographic Assessment of Aortic Regurgitation AfterÂTAVR. JACC: Cardiovascular Interventions, 2021, 14, 531-538.	2.9	8
24	The effect of immediate coronary angiography after cardiac arrest without ST-segment elevation on left ventricular function. A sub-study of the COACT randomised trial. Resuscitation, 2021, 164, 93-100.	3.0	9
25	Periprocedural Antibiotic Prophylaxis for Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Survey in the Netherlands. Structural Heart, 2021, 5, 328-329.	0.6	2
26	Outcome and Predictors for Mortality in Patients with Cardiogenic Shock: A Dutch Nationwide Registry-Based Study of 75,407 Patients with Acute Coronary Syndrome Treated by PCI. Journal of Clinical Medicine, 2021, 10, 2047.	2.4	5
27	Implementation of CT Coronary Angiography as an Alternative to Invasive Coronary Angiography in the Diagnostic Work-Up of Non-Coronary Cardiac Surgery, Cardiomyopathy, Heart Failure and Ventricular Arrhythmias. Journal of Clinical Medicine, 2021, 10, 2374.	2.4	0
28	Cangrelor Use in Routine Practice: A Two-Center Experience. Journal of Clinical Medicine, 2021, 10, 2829.	2.4	1
29	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1009-1015.	1.0	30
30	Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. Cardiovascular Drugs and Therapy, 2021, 35, 1171-1182.	2.6	7
31	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	2.8	111
32	XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: †The New Normal'?. Heart International, 2021, 15, 65.	1.4	1
33	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. Journal of Invasive Cardiology, 2021, 33, E823-E832.	0.4	0
34	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	1.7	4
35	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). European Heart Journal, 2020, 41, 3715-3728.	2.2	121
36	Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 108-119.	1.0	25

#	Article	IF	CITATIONS
37	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. International Journal of Cardiology, 2020, 300, 93-98.	1.7	4
38	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. European Radiology, 2020, 30, 600-608.	4.5	13
39	Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 164-172.	1.0	72
40	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	0
41	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine―in Daily Clinical Practice. Journal of Clinical Medicine, 2020, 9, 3173.	2.4	6
42	Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLoS ONE, 2020, 15, e0235762.	2.5	14
43	Brachial Artery Access as a Novel Alternative for Impella 2.5 Insertion. JACC: Case Reports, 2020, 2, 1884-1887.	0.6	3
44	Threeâ€year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€eluting stent in routine PCI in patients with diabetes mellitus— AIDA subâ€study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	1.7	1
45	Coronary Angiography After Cardiac Arrest Without ST Segment Elevation. JAMA Cardiology, 2020, 5, 1358.	6.1	65
46	Tele-ECG consulting and outcomes on primary care patients in a low-to-middle income population: the first experience from Makassar telemedicine program, Indonesia. BMC Family Practice, 2020, 21, 247.	2.9	7
47	Data on sex differences in one-year outcomes of out-of-hospital cardiac arrest patients without ST-segment elevation. Data in Brief, 2020, 33, 106521.	1.0	0
48	External validation of existing prediction models of 30-day mortality after Transcatheter Aortic Valve Implantation (TAVI) in the Netherlands Heart Registration. International Journal of Cardiology, 2020, 317, 25-32.	1.7	11
49	Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization. PLoS ONE, 2020, 15, e0234543.	2.5	12
50	Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2051.	2.4	21
51	Mechanical circulatory support for shock: AÂlittle bit better is just not enough!. Netherlands Heart Journal, 2020, 28, 177-178.	0.8	0
52	Continuous postoperative pericardial flushing method versus standard care for wound drainage after adult cardiac surgery: A randomized controlled trial. EBioMedicine, 2020, 55, 102744.	6.1	2
53	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. Journal of the American College of Cardiology, 2020, 75, 2664-2678.	2.8	93
54	Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. EuroIntervention, 2020, 16, e904-e912.	3.2	2

#	Article	IF	Citations
55	Ecological momentary assessment versus retrospective assessment for measuring change in health-related quality of life following cardiac intervention. Journal of Patient-Reported Outcomes, 2020, 4, 98.	1.9	5
56	The Impact of a Chronic Total Coronary Occlusion on Outcomes of Patients With an Implantable Cardioverter Defibrillator: Insights From the EXPLORE Trial. Journal of Invasive Cardiology, 2020, 32, E60-E62.	0.4	0
57	Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventions. Perfusion (United Kingdom), 2019, 34, 98-105.	1.0	130
58	Quantification of Myocardial Mass Subtended by a Coronary Stenosis Using Intracoronary Physiology. Circulation: Cardiovascular Interventions, 2019, 12, e007322.	3.9	10
59	Aortic valve calcification volumes and chronic brain infarctions in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiovascular Imaging, 2019, 35, 2123-2133.	1.5	12
60	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation, 2019, 140, 420-433.	1.6	263
61	3-Year Clinical Outcomes of the PRISON-IV Trial. JACC: Cardiovascular Interventions, 2019, 12, 1747-1749.	2.9	11
62	Influence of response shift and disposition on patient-reported outcomes may lead to suboptimal medical decisions: a medical ethics perspective. BMC Medical Ethics, 2019, 20, 61.	2.4	10
63	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. Journal of Radiology Case Reports, 2019, 13, 9-14.	0.4	0
64	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLOREâ€trial. Catheterization and Cardiovascular Interventions, 2019, 94, 536-545.	1.7	3
65	Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. New England Journal of Medicine, 2019, 380, 1397-1407.	27.0	373
66	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
67	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologists—insights from the RECAP trial. Netherlands Heart Journal, 2019, 27, 330-333.	0.8	4
68	The dynamics in health-related quality of life of patients with stable coronary artery disease were revealed: a network analysis. Journal of Clinical Epidemiology, 2019, 107, 116-123.	5.0	11
69	Lactate is a Prognostic Factor in Patients Admitted With Suspected ST-Elevation Myocardial Infarction. Shock, 2019, 51, 321-327.	2.1	28
70	Reconstructing Disruptive Life Events Using the RE-LIFE Questionnaire: Further Validation of the â€Narrative Meaning Making of Life Events' Model Using Multiple Mediation Analysis. Journal of Empirical Theology, 2019, 32, 251-280.	0.8	1
71	Adherence to guideline recommendations for coronary angiography in a poor South-East Asian setting: Impact on short- and medium-term clinical outcomes. Scientific Reports, 2019, 9, 19163.	3.3	4
72	CT determined psoas muscle area predicts mortality in women undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2019, 93, E248-E254.	1.7	20

#	Article	IF	CITATIONS
73	Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 338-349.	1.0	55
74	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial). American Journal of Cardiology, 2019, 123, 1035-1043.	1.6	6
75	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation, 2019, 139, 1249-1258.	1.6	353
76	Paclitaxelâ€eluting balloon versus everolimusâ€eluting stent in patients with diabetes mellitus and inâ€stent restenosis: Insights from the randomized DARE trial. Catheterization and Cardiovascular Interventions, 2019, 93, 216-221.	1.7	4
77	Angiographic and clinical outcomes of antegrade versus retrograde techniques for chronic total occlusion revascularizations: Insights from the PRISON IV trial. Catheterization and Cardiovascular Interventions, 2019, 93, E81-E89.	1.7	4
78	Left Ventricular Unloading During Veno-Arterial ECMO: A Simulation Study. ASAIO Journal, 2019, 65, 11-20.	1.6	112
79	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. EuroIntervention, 2019, 15, 603-606.	3.2	11
80	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. Heart, 2018, 104, 1432-1438.	2.9	55
81	Incidence, Predictors, and Impact of Vascular Complications After Transfemoral Transcatheter Aortic Valve Implantation With the SAPIEN 3 Prosthesis. American Journal of Cardiology, 2018, 121, 1231-1238.	1.6	41
82	Revascularization Strategies in Cardiogenic Shock Patients With MVD. Journal of the American College of Cardiology, 2018, 71, 857-859.	2.8	5
83	First report of the use of longâ€tapered sirolimusâ€eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm. Catheterization and Cardiovascular Interventions, 2018, 92, E299-E307.	1.7	13
84	1-Year Clinical Performance of COMBO Stent Versus XienceÂStent in All-Comers Patients With Coronary ArteryÂDisease. JACC: Cardiovascular Interventions, 2018, 11, 102-103.	2.9	1
85	Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. Catheterization and Cardiovascular Interventions, 2018, 92, E106-E114.	1.7	6
86	Procedural Outcome and Midterm Survival of Lower Risk Transfemoral Transcatheter Aortic Valve Implantation Patients Treated With the SAPIEN XT or SAPIEN 3 Device. American Journal of Cardiology, 2018, 121, 856-861.	1.6	13
87	Impact of ultraâ€thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial. Journal of Interventional Cardiology, 2018, 31, 580-587.	1.2	9
88	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Longâ€Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverterâ€Defibrillator (the eCTOpyâ€inâ€iCD Study). Journal of the American Heart Association, 2018, 7,	3.7	13
89	Patient delay in women with STEMI: Time to raise awareness. International Journal of Cardiology, 2018, 262, 30-31.	1.7	1
90	Comparison of Outcomes of Transfemoral Aortic Valve Implantation in Patients <90 With Those >90 Years of Age. American Journal of Cardiology, 2018, 121, 1581-1586.	1.6	18

#	Article	IF	CITATIONS
91	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 511-512.	2.9	O
92	Reply. JACC: Cardiovascular Interventions, 2018, 11, 506-507.	2.9	0
93	Electrocardiographic changes after successful recanalization of a chronic total coronary occlusion. A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2018, 19, 221-228.	0.8	10
94	Fiveâ€year followâ€up of the endothelial progenitor cell capturing stent versus the paxlitaxelâ€eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheterization and Cardiovascular Interventions, 2018, 91, 1212-1218.	1.7	4
95	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the TreatmentÂof Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	2.9	88
96	Predictors of medium-term mortality in patients hospitalised with coronary artery disease in a resource-limited South-East Asian setting. Open Heart, 2018, 5, e000801.	2.3	7
97	Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts. Coronary Artery Disease, 2018, 29, 171-173.	0.7	0
98	Clinical Implications of Distal Vessel Stenosis After Successful Coronary Chronic TotalÂOcclusion Recanalization. JACC: Cardiovascular Interventions, 2018, 11, 2343-2345.	2.9	9
99	Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. Open Heart, 2018, 5, e000833.	2.3	7
100	Guideline-defined futility or patient-reported outcomes to assess treatment success after TAVI: what to use? Results from a prospective cohort study with long-term follow-up. Open Heart, 2018, 5, e000879.	2.3	21
101	CTCA for detection of significant coronary artery disease in routine TAVI work-up. Netherlands Heart Journal, 2018, 26, 591-599.	0.8	50
102	Characteristics and the average 30-day and 6-month clinical outcomes of patients hospitalised with coronary artery disease in a poor South-East Asian setting: the first cohort from Makassar Cardiac Center, Indonesia. BMJ Open, 2018, 8, e021996.	1.9	3
103	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine, 2018, 44, 847-856.	8.2	106
104	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. Open Heart, 2018, 5, e000810.	2.3	11
105	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. Journal of Electrocardiology, 2018, 51, 906-912.	0.9	6
106	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. Structural Heart, 2018, 2, 53-57.	0.6	10
107	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. American Journal of Cardiology, 2018, 122, 1661-1669.	1.6	8
108	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention, 2018, 13, 1565-1573.	3.2	35

#	Article	IF	CITATIONS
109	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. EuroIntervention, 2018, 14, e434-e442.	3.2	14
110	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention, 2018, 14, e426-e433.	3.2	26
111	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. EuroIntervention, 2018, 14, e252-e254.	3.2	3
112	Randomized Multicenter Trial InvestigatingÂAngiographic Outcomes ofÂHybrid Sirolimus-Eluting Stents WithÂBiodegradable Polymer Compared WithÂEverolimus-Eluting Stents With DurableÂPolymer in Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2017, 10, 133-143.	2.9	83
113	Monocytic microRNA profile associated with coronary collateral artery function in chronic total occlusion patients. Scientific Reports, 2017, 7, 1532.	3.3	5
114	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2017, 69, 2347-2348.	2.8	5
115	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2017, 10, 906-914.	2.9	30
116	The ICM research agenda on extracorporeal life support. Intensive Care Medicine, 2017, 43, 1306-1318.	8.2	94
117	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: AÂweighted meta-analysis of seven randomised controlled trials including 5577 patients. Netherlands Heart Journal, 2017, 25, 429-438.	0.8	12
118	Reply. Journal of the American College of Cardiology, 2017, 69, 1758-1759.	2.8	0
119	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. New England Journal of Medicine, 2017, 376, 2319-2328.	27.0	363
120	Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2035-2040.	1.6	29
121	Predicting hospitalisation duration after transcatheter aortic valve implantation. Open Heart, 2017, 4, e000549.	2.3	10
122	Culprit Vessel–Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	44
123	Efficacy of the RADPAD Protection Drape in Reducing Operators' Radiation Exposure in the Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	48
124	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal, 2017, 38, 3523-3531.	2.2	280
125	The first generation ABSORB BVS scaffold; to be or not to be?. Netherlands Heart Journal, 2017, 25, 416-418.	0.8	4
126	Anxiety levels of patients undergoing coronary procedures in the catheterization laboratory. International Journal of Cardiology, 2017, 228, 926-930.	1.7	55

#	Article	IF	CITATIONS
127	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon PumpÂin Cardiogenic Shock After AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2017, 69, 278-287.	2.8	612
128	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock. Journal of the American College of Cardiology, 2017, 69, 358-360.	2.8	98
129	The first-generation ABSORB BVS: awaiting dissolving outcomes. Netherlands Heart Journal, 2017, 25, 650-652.	0.8	0
130	Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 53.	3.3	41
131	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. Journal of Thoracic Disease, 2016, 8, E1100-E1102.	1.4	1
132	The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the) Tj ETQqQ Interventions, 2016, 9, .	0 0 rgBT 3.9	Overlock 10
133	Percutaneous Intervention for ConcurrentÂChronic Total Occlusions inÂPatients WithÂSTEMI. Journal of the American College of Cardiology, 2016, 68, 1622-1632.	2.8	300
134	Prognostic Impact of ChronicÂTotalÂOcclusions. JACC: Cardiovascular Interventions, 2016, 9, 1535-1544.	2.9	65
135	Intracoronary Abciximab in DiabeticÂSTEMIÂPatients. Journal of the American College of Cardiology, 2016, 68, 739-741.	2.8	0
136	Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Medicine, 2016, 42, 1922-1934.	8.2	405
137	Coronary angiography after cardiac arrest: Rationale and design of the COACT trial. American Heart Journal, 2016, 180, 39-45.	2.7	28
138	Assessment of Cardiac Device Position on Supine Chest Radiograph in the ICU. Critical Care Medicine, 2016, 44, e957-e963.	0.9	3
139	Older coronary thrombus is an independent predictor of $1\hat{a} \in \mathcal{Y}$ ear mortality in acute myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 501-510.	3.4	11
140	A SMILE and a Frown. Journal of the American College of Cardiology, 2016, 67, 273-274.	2.8	8
141	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. Journal of Thrombosis and Thrombolysis, 2016, 41, 441-451.	2.1	9
142	Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock International Journal of Cardiology, 2016, 202, 894-896.	1.7	76
143	Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication. European Heart Journal, 2016, 37, 1104-1112.	2.2	6
144	Basal stenosis resistance index derived from simultaneous pressure and flow velocity measurements. EuroIntervention, 2016, 12, e199-e207.	3.2	15

#	Article	IF	CITATIONS
145	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. EuroIntervention, 2016, 12, 423-430.	3.2	8
146	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. EuroIntervention, 2016, 12, e557-e565.	3.2	11
147	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute STâ€segment elevation myocardial infarction: Results of the ⟨scp⟩ HORIZONSâ€AMI⟨/scp⟩ trial. Catheterization and Cardiovascular Interventions, 2015, 85, 335-342.	1.7	22
148	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2015, 184, 128-134.	1.7	15
149	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention — From the PROTECT II randomized trial. International Journal of Cardiology, 2015, 189, 272-278.	1.7	9
150	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. International Journal of Cardiology, 2015, 187, 90-96.	1.7	126
151	Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. Netherlands Heart Journal, 2015, 23, 161-165.	0.8	30
152	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. Netherlands Heart Journal, 2015, 23, 477-482.	0.8	8
153	Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. International Journal of Cardiology, 2015, 201, 684-691.	1.7	160
154	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. Interventional Cardiology Review, 2015, 10, 39.	1.6	2
155	Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention, 2015, 10, 1272-1275.	3. 2	9
156	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention, 2015, 10, 1160-1168.	3.2	118
157	Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography. EuroIntervention, 2015, 11, 877-884.	3.2	13
158	Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemia. EuroIntervention, 2015, 11, 914-925.	3.2	62
159	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , $2015,,2281\text{-}2296.$		0
160	First report on longâ€term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent. Catheterization and Cardiovascular Interventions, 2014, 84, 759-765.	1.7	8
161	Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. Heart, 2014, 100, 951-959.	2.9	102
162	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). American Journal of Cardiology, 2014, 113, 222-228.	1.6	116

#	Article	IF	Citations
163	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	2.1	49
164	The Prognostic Value of Bleeding Academic Research Consortium (BARC)-Defined BleedingÂComplications in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1866-1875.	2.8	93
165	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	2.9	34
166	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	2.9	159
167	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	13.7	33
168	Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent. Heart, 2014, 100, 479-486.	2.9	14
169	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 294.	0.9	7
170	Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity. Circulation: Cardiovascular Interventions, 2014, 7, 301-311.	3.9	322
171	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	1.6	25
172	Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. American Heart Journal, 2014. 167, 472-479.e5.	2.7	34
173	2014, 167, 472,479,e5 Amsterdam Investigatora ← initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale	2.7	41
174	Admission Lipoprotein-Associated Phospholipase A2 Activity Is Not Associated with Long-Term Clinical Outcomes after ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2014, 9, e96251.	2.5	2
175	Chronic Total Occlusions in Sweden – A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). PLoS ONE, 2014, 9, e103850.	2.5	108
176	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention, 2014, 10, 90-96.	3.2	26
177	Increased hyperaemic coronary microvascular resistance adds to the presence of myocardial ischaemia. EuroIntervention, 2014, 9, 1423-1431.	3.2	23
178	MGuard Embolic Protection Stent – The Importance of Thrombus Management in ST-elevation Myocardial Infarction Primary Percutaneous Coronary Intervention. Interventional Cardiology Review, 2014, 9, 168.	1.6	0
179	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439.	2.6	12
180	Percutaneous Mechanical Support. Interventional Cardiology Clinics, 2013, 2, ix.	0.4	0

#	Article	IF	Citations
181	The impact of multivessel disease with and without a coâ€existing chronic total occlusion on short― and longâ€term mortality in STâ€elevation myocardial infarction patients with and without cardiogenic shock. European Journal of Heart Failure, 2013, 15, 425-432.	7.1	90
182	Clinical outcomes after bareâ€metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheterization and Cardiovascular Interventions, 2013, 81, 26-33.	1.7	3
183	Short―and Longâ€Term Prognostic Value of the TIMI Risk Score after Primary Percutaneous Coronary Intervention for STâ€segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 8-13.	1.2	9
184	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	2.1	6
185	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2013, 2, 665-670.	0.4	O
186	Additional side branch stent placement in patients with long side branch lesions treated with the Tryton dedicated bifurcation side branch stent. International Journal of Cardiology, 2013, 168, 3059-3062.	1.7	0
187	A Systematic Review and Meta-Analysis on Primary Percutaneous Coronary Intervention of an Unprotected Left Main Coronary Artery Culprit Lesion in the Setting of Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 317-324.	2.9	48
188	Impact of target vessel on longâ€term survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	1.7	46
189	Impact of Coronary Microvascular Function on Long-term Cardiac Mortality in Patients With Acute ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 207-215.	3.9	77
190	The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. Journal of Medical Economics, 2013, 16, 381-390.	2.1	28
191	Impaired Coronary Autoregulation Is Associated With Long-term Fatal Events in Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2013, 6, 329-335.	3.9	65
192	Percutaneous Left-Ventricular Support With the Impella-2.5–Assist Device in Acute Cardiogenic Shock. Circulation: Heart Failure, 2013, 6, 23-30.	3.9	278
193	Timing of Mortality After Severe Bleeding and Recurrent Myocardial Infarction in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 391-398.	3.9	28
194	Clinical and Procedural Characteristics Associated With Higher Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiography. Circulation: Cardiovascular Interventions, 2013, 6, 501-506.	3.9	58
195	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, 922-929.	1.7	16
196	Longâ€term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	1.7	24
197	Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI. Thrombosis and Haemostasis, 2013, 109, 961-970.	3.4	11
198	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. EuroIntervention, 2013, 9, 195-203.	3.2	27

#	Article	IF	CITATIONS
199	Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention, 2013, 9, 841-853.	3.2	24
200	Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations. Heart, 2012, 98, 1246-1254.	2.9	62
201	A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circulation, 2012, 126, 1717-1727.	1.6	680
202	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. European Heart Journal, 2012, 33, 768-775.	2.2	206
203	Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. European Heart Journal, 2012, 33, 1076-1084.	2.2	44
204	A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. Trials, 2012, 13, 240.	1.6	10
205	Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiograms Performed by the Radial Compared With the Femoral Route. JACC: Cardiovascular Interventions, 2012, 5, 752-757.	2.9	41
206	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	2.9	101
207	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	2.1	14
208	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. Journal of Invasive Cardiology, 2012, 24, 484-8.	0.4	25
209	Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 29-36.	2.8	91
210	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	2.9	260
211	Twoâ€year followâ€up of the genousâ,,¢ endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with <i>De Novo</i> coronary artery lesions with a highâ€risk of restenosis. Catheterization and Cardiovascular Interventions, 2011, 78, 189-195.	1.7	38
212	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. EuroIntervention, 2011, 6, 860-865.	3.2	26
213	Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. Journal of Cardiovascular Medicine, 2010, 11, 827-831.	1.5	7
214	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. Netherlands Heart Journal, 2010, 18, 451-453.	0.8	24
215	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. American Journal of Cardiology, 2010, 105, 955-959.	1.6	105
216	Effects of mechanical left ventricular unloading by impella on left ventricular dynamics in highâ€risk and primary percutaneous coronary intervention patients. Catheterization and Cardiovascular Interventions, 2010, 75, 187-194.	1.7	91

#	Article	IF	CITATIONS
217	Longâ€term followâ€up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. Catheterization and Cardiovascular Interventions, 2010, 75, 1026-1036.	1.7	4
218	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Trials, 2010, 11, 89.	1.6	58
219	A single dose of erythropoietin in ST-elevation myocardial infarction. European Heart Journal, 2010, 31, 2593-2600.	2.2	144
220	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart, 2010, 96, 843-847.	2.9	60
221	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. Heart, 2010, 96, 1968-1972.	2.9	52
222	Sensor-Augmented Insulin Pump Therapy to Treat Hyperglycemia at the Coronary Care Unit: A Randomized Clinical Pilot Trial. Diabetes Technology and Therapeutics, 2010, 12, 537-542.	4.4	9
223	Right ventricular dysfunction is an independent predictor for mortality in STâ€elevation myocardial infarction patients presenting with cardiogenic shock on admission. European Journal of Heart Failure, 2010, 12, 276-282.	7.1	57
224	Genousâ,,¢ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. European Heart Journal, 2010, 31, 1055-1064.	2.2	106
225	Percutaneous assist devices vs. intra-aortic balloon pump for cardiogenic shock: evidence under construction vs. expert opinion. European Heart Journal, 2010, 31, 502-502.	2.2	2
226	Current status of the Xience V $<$ sup $>$ Â $^{®}<$ /sup $>$ everolimus-eluting coronary stent system. Expert Review of Cardiovascular Therapy, 2010, 8, 1363-1374.	1.5	11
227	Percutaneous left ventricular assist devices for high-risk percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2010, 8, 1247-1255.	1.5	4
228	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission Acute Cardiac Care, 2010, 12, 51-57.	0.2	24
229	Histopathological Features of Aspirated Thrombi after Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction. PLoS ONE, 2009, 4, e5817.	2.5	49
230	Role of fractional and coronary flow reserve in clinical decision making in intermediate coronary lesions. Interventional Cardiology, 2009, 1, 237-255.	0.0	24
231	Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. Acute Cardiac Care, 2009, 11, 107-112.	0.2	10
232	Comparison of Long-Term Mortality After Percutaneous Coronary Intervention in Patients Treated for Acute ST-Elevation Myocardial Infarction Versus Those With Unstable and Stable Angina Pectoris. American Journal of Cardiology, 2009, 104, 333-337.	1.6	40
233	Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. Clinical Research in Cardiology, 2009, 98, 311-318.	3.3	63
234	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2009, 2, 1128-1134.	2.9	208

#	Article	IF	CITATIONS
235	A Prospective Feasibility Trial Investigating the Use of the Impella 2.5 System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (The PROTECT I Trial). JACC: Cardiovascular Interventions, 2009, 2, 91-96.	2.9	295
236	Supported High-Risk Percutaneous Coronary Intervention With the Impella 2.5 Device. Journal of the American College of Cardiology, 2009, 54, 2430-2434.	2.8	210
237	Left Ventricular Unloading in Acute ST-Segment Elevation Myocardial Infarction Patients Is Safe and Feasible and Provides Acute and Sustained Left Ventricular Recovery. Journal of the American College of Cardiology, 2008, 51, 1044-1046.	2.8	89
238	Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention. Circulation, 2008, 118, 1810-1816.	1.6	135
239	A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. European Heart Journal, 2008, 30, 459-468.	2.2	452
240	Interferon-Î ² Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice. Circulation Research, 2008, 102, 1286-1294.	4.5	66
241	New percutaneous mechanical left ventricular support for acute MI: the AMC MACH program. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 62-63.	3.3	11
242	Demonstrating LV unloading on echocardiography during high risk PCI with a left ventricular assist device. Acute Cardiac Care, 2007, 9, 125-126.	0.2	3
243	Percutaneous mechanical cardiac assist in myocardial infarction. Where are we now, where are we going?. Acute Cardiac Care, 2007, 9, 222-230.	0.2	24
244	In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. American Heart Journal, 2007, 154, 1184-1190.	2.7	43
245	Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheterization and Cardiovascular Interventions, 2007, 70, 532-537.	1.7	161
246	Prognostic Value of Admission Hemoglobin Levels in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. American Journal of Cardiology, 2007, 99, 1201-1202.	1.6	38
247	Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5. American Journal of Cardiology, 2006, 97, 990-992.	1.6	205
248	Impact of Multivessel Coronary Disease on Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Is Due to the Presence of a Chronic Total Occlusion. American Journal of Cardiology, 2006, 98, 1165-1169.	1.6	126
249	Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. European Heart Journal, 2006, 27, 2499-2510.	2.2	97
250	Plaque Instability Frequently Occurs Days or Weeks Before Occlusive Coronary Thrombosis. Circulation, 2005, 111, 1160-1165.	1.6	287
251	Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. American Heart Journal, 2004, 148, 399-404.	2.7	124
252	Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade. Circulation, 2003, 107, 2115-2119.	1.6	350